文献速递生殖医学

使用己酮可可碱识别不动精子行ICSI周期的产科和新生儿结局

Obstetric and neo-natal outcomes of ICSI cycles using pentoxifylline to identify viable spermatozoa in patients with immotile spermatozoa.
PubMed 文献 · Reprod Biomed Online · 2017-01-24

该研究对西班牙和意大利四个IVF中心102例经己酮可可碱(PF)ICSI获得临床妊娠的患者进行产后随访,共登记134例临床妊娠中122名婴儿,单人胎低出生体重率6.1%、早产率12%,活产畸形率4/122(3.3%,95%CI 0.9-8.2%),结果未提示不良结局增加。

要点

  • PF-ICSI后活产儿ICD-10畸形率为3.3%(95%CI 0.9-8.2%)。
  • 单人胎低出生体重(≤2500 g)率6.1%,早产(<37周)率12%。
  • 结果基于有限队列,未提示PF-ICSI增加不良产科或新生儿结局。

核心结论

  • 这是首份关于PF-ICSI新生儿结局的报告,虽基于有限队列,结果未提示该操作后不良结局(包括畸形率)增加。

研究设计与样本

  • 对西班牙和意大利四个IVF中心102例经PF-ICSI获得临床妊娠的患者进行产后随访。
  • 共登记134例临床妊娠中的122名婴儿(82名单胎、40名双胎)。
  • 新生儿畸形按世界卫生组织国际疾病分类(ICD-10,Q00-Q99范围)分类。

主要发现

  • 活产儿中记录4/122名(3.3%,95%CI 0.9-8.2%)婴儿存在ICD-10畸形。
  • 单人胎中低出生体重(≤2500 g)率为6.1%,早产(<37周)率为12%。
  • 畸形率与文献报道的常规IVF或ICSI子代ICD-10编码频率5.3%和4.4%相比较。

关键数值与推荐

  • 新生儿畸形按ICD-10(Q00-Q99范围)分类。
  • 低出生体重定义为≤2500 g,早产定义为<37周。
  • 比较数据为其他团队发表的常规IVF或ICSI子代ICD-10编码频率5.3%和4.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出该报告基于有限队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pentoxifylline (PF) represents an effective tool in stimulating motility and identifying viable spermatozoa in intracytoplasmic sperm injection (ICSI) patients presenting exclusively with immotile spermatozoa. However, its use is not universally accepted for its possible detrimental effects on oocytes, embryos or newborns. To evaluate whether PF use may affect obstetrical/neo-natal outcomes, 102 patients achieving a clinical pregnancy after a PF-ICSI in four IVF units in Spain and Italy were followed up after delivery. Neo-natal malformations were classified according to the World Health Organization International Classification of Diseases (ICD-10, range Q00-Q99). Malformation rate was compared with data published by other groups regarding children conceived by conventional IVF or ICSI reporting a 5.3% and 4.4% frequency of ICD-10 codes, respectively. Of 134 clinical pregnancies, 122 babies (82 singletons and 40 twins) were registered. Among singletons, the rates of low birthweight (≤2500 g) and preterm birth (<37 weeks) were 6.1% and12%, respectively. Regarding malformation rate per live births, 4/122 (3.3%, 95% confidence interval: 0.9-8.2%) babies with ICD-10 malformations were recorded. This is the first report on neo-natal outcomes deriving from PF-ICSI. Although based on a limited cohort, results do not suggest an increase of adverse outcomes, including malformation rates, following this procedure.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Navas P, Paffoni A, Intra G, et al. Obstetric and neo-natal outcomes of ICSI cycles using pentoxifylline to identify viable spermatozoa in patients with immotile spermatozoa. Reprod Biomed Online. 2017. PMID: 28162936. doi:10.1016/j.rbmo.2017.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。